China National Medicines (SHSE:600511) Insider Ownership: 0.00 % (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600511 China National Medicines Corp Ltd SHSE:600511
87 GF Score
Price ¥26.27
GF Value ¥32.22
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is China National Medicines Insider Ownership?

China National Medicines SHSE:600511 +0.81% 87 Insider Ownership is 0.00 % as of Sep. 21, 2026. GuruFocus rates SHSE:600511 with a GF Score™ of 87/100 and a GF Value™ of ¥32.22 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, China National Medicines's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, China National Medicines's Institutional Ownership is 2.83%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, China National Medicines's Float Percentage Of Total Shares Outstanding is 0.00%.

China National Medicines Insider Ownership Historical Data

* Premium members only.

The historical data trend for China National Medicines's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China National Medicines Insider Ownership Chart

China National Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

China National Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
SHSE:600511
87GF Score
China National Medicines Corp Ltd SHSE:600511
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China National Medicines Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
China National Medicines (SHSE:600511) has a Insider Ownership of 0.00 % as of Sep. 21, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on China National Medicines and its competitors.
Is China National Medicines' Insider Ownership too high?
China National Medicines' current Insider Ownership is 0.00 %. Overall, China National Medicines has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Medicines' Insider Ownership compare to MCK and COR?
China National Medicines' Insider Ownership of 0.00 % can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Medical Distribution company?
A good Insider Ownership depends on the Medical Distribution industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on China National Medicines and its competitors. China National Medicines's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Medicines (SHSE:600511) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥32.22, compared to a current price of ¥26.27 — trading 18.5% below its estimated fair value. The current Insider Ownership is 0.00 %. China National Medicines' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For China National Medicines (SHSE:600511), the current Insider Ownership is 0.00 % as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China National Medicines (SHSE:600511) Overvalued in 2026?

Based on GuruFocus' analysis, China National Medicines stock appears to be undervalued. The current stock price of ¥26.27 is trading 18.5% below its estimated GF Value™ of ¥32.22. GuruFocus considers China National Medicines to be Modestly Undervalued.

Key valuation signals for SHSE:600511:

  • Insider Ownership: 0.00 %
  • GF Value™: ¥32.22 vs. price of ¥26.27 (18.5% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600511 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China National Medicines Business Description

Address No. 8, Xibinhe Road, Floor 6-9, West Tower, 7th Floor, Yongdingmen, Dongcheng District, Beijing, CHN, 100077
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company conducts its operations through two primary segments. The Commercial segment is mainly engaged in the sale of pharmaceuticals. The Others segment focuses on pharmaceutical manufacturing and logistics operations.
87GF Score

Get the complete analysis for SHSE:600511

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥26.27
Price
¥32.22
GF Value